Loading research…
Beta Drugs Ltd. (NSE: BETA)
Beta Drugs Ltd. trades on NSE under the symbol BETA, quoted in INR. The listing is associated with India. Its sector is Health technology, within Pharmaceuticals: major. Reported figures retain their financial periods. Market prices and charts are shown separately from dated research.
- Exchange
- NSE
- Country
- India
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Trading currency
- INR
- ISIN
- INE351Y01019
Reported financials
Research date October 28, 2026. Figures below are dated observations, not market quotes.
| Metric | Value | Period | Period end |
|---|---|---|---|
| Revenue | 46,275,246.48 USD | TTM | Sep 30, 2026 |
| Net income | 5,407,853.09 USD | TTM | Sep 30, 2026 |
| Diluted EPS | 0.51 USD | TTM | Sep 30, 2026 |
| Total assets | 53,015,851.23 USD | Annual | Mar 31, 2026 |
| Total debt | 16,111,346.27 USD | Annual | Mar 31, 2026 |
| Gross margin | 36.57% | TTM | Sep 30, 2026 |
| Operating margin | 16.69% | TTM | Sep 30, 2026 |
| Return on equity | 15.76% | TTM | Sep 30, 2026 |
| Return on assets | 9.08% | TTM | Sep 30, 2026 |
| Dividend per share | 0.00 USD | Annual | Mar 31, 2026 |
Stock ScreenerEarnings CalendarDividends CalendarStock investing guide
Data notes
Scores, valuation models and research metrics use dated FOLITIC research. Dates and currencies remain attached to their observations. Missing values are shown as a dash.
Market quotes and charts use the separate market-data display. Saved research prices and model comparisons are not live quotes. Model ranges represent sensitivity scenarios, not confidence intervals or price guarantees.
Listings on different exchanges and different share classes are kept separate. No currency conversion is applied to saved research values.